TB-500 is, along with BPC-157, one of the two headline "healing peptides" of the biohacker era. It is sold as a synthetic version of thymosin beta-4, promoted for tendon repair, muscle injury recovery, cardiac regeneration, and a long tail of inflammatory and tissue-remodeling indications. The problem begins with the name: the compound sold as TB-500 is not actually thymosin beta-4. It is a smaller, synthetic fragment loosely derived from the parent protein. The distinction matters because the real clinical evidence — such as it is — almost all concerns the full-length thymosin beta-4, while the injectable product marketed to consumers is something different. This article sorts out the confusion and grades the evidence honestly.
⚕️ Regulatory & Safety Notice
TB-500 is not FDA-approved for any indication. The World Anti-Doping Agency added thymosin beta-4 and related peptides to its prohibited list in 2011. In 2023 the FDA moved thymosin beta-4 off the 503A bulk compounding allowed list, effectively ending legal pharmacy compounding for human use in the United States. Any injectable product sold as "TB-500" online is a research chemical of unverified identity and purity. Nothing in this article is medical advice.
What Is TB-500?
To answer this question honestly, two separate molecules need to be kept straight.
Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide first isolated from bovine thymus in the 1980s. It is one of the most abundant intracellular proteins in mammalian cells, where its primary function is to sequester monomeric G-actin and regulate the dynamics of the actin cytoskeleton. It is encoded by the TMSB4X gene in humans, it circulates in plasma at detectable levels, and it has been the subject of a legitimate clinical development program by RegeneRx Biopharmaceuticals for dry eye disease, wound healing, and cardiovascular applications.
TB-500, as it is sold on gray-market peptide websites, is something narrower. The identity of the molecule actually shipped under this name varies by vendor, but most commonly it refers to a small synthetic fragment — often the tetrapeptide Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-prolyl) or closely related short fragments derived from the amino-terminus of thymosin beta-4. Ac-SDKP is a real biologically active peptide, it is produced endogenously by proteolytic cleavage of Tβ4, and it has documented effects in cardiac remodeling and fibrosis models. But it is not the same molecule as full-length Tβ4.
The slippage matters because vendors and customers cite Tβ4 literature (clinical dry-eye trials, cardiac studies) as evidence for the injectable "TB-500" product, when the two are chemically and pharmacologically distinct. Reading the gray-market materials, you will encounter the full 43-amino-acid sequence diagram printed on spec sheets for vials that, on assay, contain something smaller. This is either a labeling problem or a fundamental product-identity problem, depending on your generosity toward peptide vendors.
Mechanism
Two related but distinct mechanisms are at play depending on which molecule you are discussing.
Full-length thymosin beta-4 acts primarily through its actin-sequestering function. By binding monomeric G-actin, it regulates the availability of actin monomers for filament formation — a central control point for cell motility, cytoskeletal remodeling, wound closure, and angiogenesis. Tβ4 released extracellularly from injured or apoptotic cells appears to signal to neighboring cells through mechanisms that include activation of integrin-linked kinase, upregulation of vascular endothelial growth factor, and stimulation of endothelial cell migration. The proposed therapeutic effects — accelerated corneal wound healing, post-infarct cardiac repair, dermal wound closure — are all downstream of these cytoskeletal and angiogenic activities.
Ac-SDKP is different. It was originally characterized as a natural inhibitor of hematopoietic stem cell proliferation, and later shown to have anti-fibrotic effects in cardiac and renal injury models. It is a substrate for angiotensin-converting enzyme (ACE), which is why ACE inhibitor therapy elevates plasma Ac-SDKP concentrations. Its therapeutic story is plausible and has some preclinical support, but it is a separate story from Tβ4's actin regulation.
Conflating the two mechanisms is the central conceptual error behind most "TB-500" marketing.
Evidence
Thymosin beta-4 clinical data. RegeneRx advanced Tβ4 into multiple Phase 2 and Phase 3 trials, most notably for neurotrophic keratopathy and dry eye disease. A Phase 3 trial of topical Tβ4 (branded RGN-259) for neurotrophic keratopathy reported improvements in corneal healing outcomes (Sosne et al., 2015 and later publications). Dry eye data has been mixed, with some trials missing primary endpoints and others showing modest symptomatic improvements. A Phase 2 trial of systemic Tβ4 following acute myocardial infarction was initiated but did not yield transformative results. The picture that emerges is of a molecule with real, modest biological activity in specific wound-healing contexts, not a miracle regenerator.
TB-500 / Ac-SDKP data. There are no randomized controlled trials of injectable "TB-500" as sold by peptide vendors, for any indication, in humans. The evidence base for systemic Ac-SDKP administration comes almost entirely from animal studies of cardiac and renal fibrosis (Rasoul et al., 2004; Rhaleb et al., 2011), where the peptide showed anti-fibrotic effects but was not developed as a systemic therapeutic.
Anecdotal human use. The gray-market use of TB-500 in athletes, horses, and biohackers generates extensive self-reported improvement in injury recovery, but self-report data cannot distinguish drug effect from natural healing, placebo, and concurrent treatments.
Horse racing and WADA. TB-500 first came to widespread attention through thoroughbred racing, where it was used for tendon and ligament injuries in performance horses. WADA banned thymosin beta-4 and related peptides in 2011 under the S2 category (peptide hormones, growth factors, related substances, and mimetics). A number of high-profile anti-doping cases in racing and other sports have involved TB-500 specifically.
Putting this together: the evidence tier for full-length Tβ4 is moderate preclinical, limited clinical, with one or two specific indications (topical corneal healing) showing signal. The evidence tier for injectable TB-500 as actually sold and used is essentially zero human data, supported by cross-contamination from the Tβ4 literature.
Applications and Claims
Common claims for TB-500 include:
- Tendon and ligament injury repair
- Muscle recovery after exercise
- Hair regrowth
- Cardiac repair post-infarction
- Anti-inflammatory effects
- Joint recovery and cartilage support
- Combined with BPC-157 as a "healing stack"
The strongest claims are the ones that map to mechanisms with actual preclinical support: angiogenesis-dependent wound healing and anti-fibrotic effects in heart and kidney injury models. The weaker claims are the generalized "recovery from any injury" framing that treats TB-500 as a universal tissue-repair agent without specific indication data.
The parallel to BPC-157 is nearly exact: both are promoted as healing peptides, both have substantial preclinical literature concentrated in a narrow set of research groups, both lack meaningful human RCT evidence for the applications they are sold for, and both have become core components of biohacker "recovery stacks" despite their unresolved regulatory status. For a longer discussion of the evidence problem in this category, see our review of BPC-157.
Connection to Gene Editing
Tissue repair is one of the domains where peptide therapeutics and gene-editing or cell-therapy approaches most directly compete. The question TB-500 implicitly raises — can exogenous administration of a pro-regenerative peptide accelerate endogenous repair? — is being answered in parallel by gene-therapy programs that deliver regenerative factors directly to injured tissue, and by cell therapies (MSCs, iPSC-derived cardiomyocytes) that aim to replace damaged tissue rather than stimulate its repair.
Thymosin beta-4 itself sits inside a broader biology of cytoskeletal regulation and stem cell activation that has been explored in regenerative medicine for over two decades. CRISPR-based approaches to cardiac repair, for instance, include strategies to reprogram fibroblasts into cardiomyocytes in situ — a genuinely regenerative intervention rather than a peptide nudge. For the underlying editing toolkit, see what is CRISPR.
The contrast illustrates why the "TB-500 for tissue repair" pitch is simultaneously compelling and frustrating. The biology of actin-mediated regeneration is real. The clinical tools that actually exploit it at scale will probably not be an unregulated injectable peptide; they will be better-characterized molecules with defined manufacturing, or gene and cell therapies with durable effects. TB-500 is a bridge product from an earlier era of peptide enthusiasm into a future that may not include it.
Limitations
Identity problem. You do not know with certainty what is in a vial of TB-500. Full-length Tβ4, Ac-SDKP, or something in between — and assay data from independent labs on various vendor products has reported all of the above.
No human RCTs for the injectable product. Every claim beyond "plausible preclinical signal" requires extrapolation.
Unknown long-term safety. The theoretical risks of chronically elevated circulating tissue-repair signaling include promotion of angiogenesis in occult tumors (a concern raised in the literature for several pro-angiogenic peptides) and effects on cell motility that could in principle affect metastatic behavior. Neither risk has been quantified in humans.
Purity and endotoxin. Gray-market peptide injection carries all the generic risks of unregulated sterile products: contamination, incorrect sequence, incorrect dose.
Regulatory and sporting consequences. WADA-banned since 2011, off-label prescribing pathway closed by the 2023 503A action.
FAQ
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-amino-acid natural peptide. TB-500 as sold to consumers is usually a shorter synthetic fragment, most commonly Ac-SDKP or closely related short peptides, though vendor identity varies.
Is TB-500 legal?
It is not FDA-approved, and as of 2023 it cannot be legally compounded for human use in the United States. It remains sold as a "research chemical" through gray-market vendors. It is banned by WADA.
Does TB-500 actually heal injuries?
Full-length thymosin beta-4 has modest preclinical and limited clinical evidence for wound healing, primarily topical corneal applications. There are no controlled human trials of injectable TB-500 for tendon, ligament, or muscle injuries.
Why is TB-500 stacked with BPC-157?
Both are promoted as tissue-repair peptides with complementary proposed mechanisms (angiogenesis + cytoprotection). The stack is biohacker convention, not evidence-based protocol.
Is TB-500 safe?
Short-term safety in animal studies has generally been acceptable. Long-term safety in humans has not been studied. Theoretical concerns about promoting angiogenesis in undetected tumors have not been quantified.
Why did the FDA restrict it in 2023?
The FDA's 2023 503A action reclassified several peptides — including thymosin beta-4, BPC-157, CJC-1295, and ipamorelin — as category 2, meaning they cannot be used in compounded preparations due to insufficient safety data and identity concerns.
